IGM Biosciences, Inc.: 5%+ holders

IGM Biosciences, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-09. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Redmile Group, LLC

Item 4 of the Prior Schedule 13D is hereby amended and supplemented in its entirety by adding the following paragraphs prior to the last paragraph of Item 4: The Tender Offer and the Merger On August 14, 2025, pursuant to the terms of the previously announced agreement and plan of merger, dated June 1, 2025 (the "Merger Agreement"), by an among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed its tender offer (the "Offer") to acquire all of the Issuer's issued and outstanding Common Stock and Non-Voting Common Stock (the "Issuer Shares") in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of the CVR Agreement described below (the "Purchase Price"). The Offer was subject to certain conditions, including among others that more than 50% of the Issuer's outstanding Common Stock be validly tendered in the Offer, inclusive of the shares of Common Stock owned by Parent and its affiliates. The Offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). Redmile and the Redmile Funds tendered 100% of their Issuer Shares to Merger Sub by the Offer Closing in exchange for the aggregate Purchase …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-15; the filing has the rest

Topsoe Holding A/S

Item 4 of Schedule 13D is hereby amended and supplemented as follows: On July 1, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Concentra Biosciences, LLC, a Delaware limited liability company ("Concentra"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Concentra ("Merger Sub"). The Merger Agreement provides for, among other things: (i) the acquisition of all of the Issuer's outstanding shares of common stock, par value $0.01 per share (the "Common Stock"), by Concentra through a cash tender offer (the "Offer"), for a price per share of the Common Stock of (A) $1.247 in cash (the "Cash Amount"), subject to applicable tax withholding and without interest; plus (B) one contingent value right (a "CVR") (such amount being the "CVR Amount" and the Cash Amount plus the CVR Amount, collectively being the "Offer Price") and (ii) the merger of Merger Sub with and into the Issuer (the "Merger") with the Issuer surviving the Merger. The foregoing description of the Merger Agreement and the transactions contemplated thereby is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on July 1, 2025.Item 4 of the SCHEDULE 13D/A filed 2025-08-18

Baker Bros. Advisors LP

Item 4 of the Schedule 13D is supplemented and amended, as the case may be, as follows: This Amendment No. 8 is being filed to report the disposition of shares of the common stock ("Common Stock") of IGM Biosciences, Inc. (the "Issuer"), shares of non-voting common stock of the Issuer that were convertible at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock ("Non-Voting Common Stock"), prefunded warrants of the Issuer that were exercisable on a 1-for-1 basis at any time at the option of the holder with no expiration date to purchase Common Stock at an exercise price of $0.01 per share ("Prefunded Warrants") and non-qualified options to purchase Common Stock ("Stock Options"), in connection with the consummation of the transactions (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of July 1, 2025 (the "Merger Agreement"), by and among the Issuer, Concentra Biosciences, LLC (the "Parent") and Concentra Merger Sub V, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at the effective time of the Merger on August 14, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on August 14, 2025, Parent completed a tender offer to purchase each issued and outstanding share of Common Stock and Non-Voting Common Stock in exchange for (i) $1.247 in cash per share of Common …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-18; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes